acf/google-ad-placement

<ul>
	<li>Health Canada&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/04/n26661174/health-canada-approves-keytruda-pembrolizumab-for-the-treatment-of-adult-patients-with-high-risk-e" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">has approved</a>&nbsp;Merck &amp; Co Inc&nbsp;MRK Keytruda (pembrolizumab) for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) setting.</li>
	<li>The approval covers Keytruda combined with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.</li>
	<li>Related:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/22/03/26296857/emas-advisory-group-backs-approval-for-mercks-keytruda-in-various-cancer-settings" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">EMA&#39;s Advisory Group Backs Approval For Merck&#39;s Keytruda In Various Cancer Settings</a>.</li>
	<li>The nod is based on Phase 3 KEYNOTE-522 trial results, demonstrating a statistically significant improvement in patients&#39; event-free survival (EFS) and pathological complete response (pCR) rate.</li>
	<li>Keytruda was first approved in Canada in 2015 and currently has cancer indications.</li>
	<li>Price Action:&nbsp;MRK shares are up 0.07% at $86.97 during the premarket session on Monday&#39;s last check.</li>
</ul>

Comments